Genodermatoses care in the Mediterranean region: a new initiative.

: TB is mainly concentrated in developing countries and global control efforts have been hampered by the deficiencies of diagnostic, prophylactic and therapeutic tools. This article looks at the need for new TB therapies and how the Stop TB Partnership's Working Group on New TB Drugs has positively influenced the TB drugs pipeline. This has involved developing a revolutionary concept for TB drug development and leveraging the potential of the existing drugs pipeline. As part of the process, there is also a need for broader collaboration to identify new candidate compounds, expand clinical trial capacity, advance new technologies and ensure regulatory harmonization.